



ASX ANNOUNCEMENT

17 August 2016

Expiry of Unlisted Options

Cynata Therapeutics Ltd (ASX: CYP) hereby advises that the following options have expired:

Code	Expiry Date	Exercise Price	Options
CYPAM	17/08/2016	\$0.80	3,333,336

The total number of options remaining on issue is as follows:

Code	Expiry Date	Exercise Price	Options
CYPAK	09/09/2016	\$0.40	500,000
CYPAI	27/09/2018	\$0.40	5,000,000
CYPAN	16/12/2018	\$0.49	750,000
CYPAM	22/02/2019	\$0.53	600,000
CYPAM	17/07/2020	\$1.00	3,666,669
			10,516,669

Media contacts: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ platform provides a source of MSCs that is independent of donor limitations and provides an “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.